Parabilis Medicines PBLS
$27.44 −$0.19 (-0.67%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $27.44 0.00%
Open$27.07
Prev close$27.63
Day range$26.50 – $28.52
Volume1.25M
Market cap$3.44B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q2, ended Jun 2026
Revenue$148,000.00
Operating profit-$50.89M-39.3% YoY
Net profit-$52.46M-50.7% YoY
Diluted EPS-$2.32-314.6% YoY
Free cash flow-$4.24M+86.4% YoY
Operating cash flow-$3.62M
Revenue, last 4 quarters
Net profit, last 4 quarters
Diluted EPS by quarter
Free cash flow by quarter
Profitability & balance sheet
Operating margin-117,335.8%
Net margin-156,531.8%
Return on equity-22.1%
Return on assets-19.7%
Return on invested capital-21.7%
Current ratio17.91
Liabilities / assets10.9%
Cash & investments$1.12B
Total debt$39.25M
Net cash (debt)$1.08B
Balance sheet
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2024 ANNUAL |
|---|---|---|---|---|
| Other Current Assets | $4.70M | $3.03M | $1.65M | $3.87M |
| Payables | $18.53M | $15.25M | $17.27M | $9.51M |
| -Accounts Payable | $18.53M | $15.04M | $17.27M | $9.51M |
| Current Accrued Expenses | $10.29M | $13.94M | $8.33M | $6.55M |
| Short-Term Debt and Capital Lease Obligation | $13.97M | $17.43M | $20.89M | $9.38M |
| -Current Debt | $5.71M | $9.40M | $13.08M | $2.50M |
| -Current Capital Lease Obligation | $8.26M | $8.03M | $7.81M | $6.88M |
| Current Deferred Liabilities | $10.37M | – | – | – |
| Total Current Liabilities | $62.84M | $54.24M | $56.79M | $32.41M |
| Total Liabilities | $127.53M | $139.95M | $97.34M | $92.81M |
| Total Assets | $1.18B | $384.17M | $80.82M | $149.25M |
| Total Current Assets | $1.13B | $332.07M | $29.36M | $92.21M |
| Cash and Cash Equivalents & Short-Term Investments | $1.12B | $329.04M | $27.71M | $87.98M |
| -Cash and Cash Equivalents | $1.09B | $329.04M | $27.71M | $47.28M |
| -Short Term Investments | $33.64M | – | $0.00 | $40.69M |
| Total Non-Current Assets | $49.87M | $52.10M | $51.46M | $57.05M |
| Net PPE | $42.73M | $44.36M | $46.08M | $52.93M |
| -Gross PPE | $56.69M | $57.73M | $58.89M | $63.38M |
| -Accumulated Depreciation | -$13.97M | -$13.38M | -$12.81M | -$10.45M |
| Other Non-Current Assets | $7.14M | $7.75M | $5.39M | $4.12M |
| Long Term Debt and Capital Lease Obligation | $33.54M | $35.71M | $37.81M | $56.82M |
| -Long Term Capital Lease Obligation | $33.54M | $35.71M | $37.81M | $44.03M |
| Non-Current Deferred Liabilities | $31.15M | – | – | – |
| Total Equity | $1.05B | $244.22M | -$16.52M | $56.44M |
| Stockholders' Equity | $1.05B | $244.22M | -$16.52M | $56.44M |
| Capital Stock | $12,000.00 | $814.54M | $509.97M | $440.38M |
| -Common Stock | $12,000.00 | $0.00 | $0.00 | $0.00 |
| -Preferred Stock | $0.00 | $814.54M | $509.97M | $440.38M |
| Additional Paid-In Capital | $1.69B | $16.50M | $15.01M | $11.66M |
| Retained Earnings | -$639.28M | -$586.82M | -$541.50M | -$395.62M |
| Other Current Liabilities | $4.23M | $3.88M | $1.22M | $622,000.00 |
| Total Non-Current Liabilities | $64.69M | $85.71M | $40.55M | $60.40M |
| Gains/Losses Not Affecting Retained Earnings | -$18,000.00 | – | $0.00 | $21,000.00 |
| Derivative Product Liabilities | – | $50.00M | – | – |
| -Due to Related Parties Current | – | $211,000.00 | – | – |
| Receivables | – | – | $0.00 | $360,000.00 |
| -Due from Related Parties Current | – | – | $0.00 | $360,000.00 |
| Convertible preferred securities | – | – | $0.00 | $2.17M |
| Other Non-Current Liabilities | – | – | $2.74M | $1.41M |
| -Long Term Debt | – | – | – | $12.79M |
Income statement
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $148,000.00 | – | – | $0.00 | – |
| Total Operating Revenue | $148,000.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $51.03M | $47.45M | $152.08M | $36.52M | $40.24M |
| Selling and Admin Expenses | $11.66M | $9.70M | $26.50M | $6.39M | $6.34M |
| Net Non-Operating Interest Income (Expense) | $3.98M | $2.14M | $1.86M | $653,000.00 | $858,000.00 |
| -General & Admin Expense | $11.66M | $9.70M | $26.50M | $6.39M | $6.34M |
| Research & Development | $39.38M | $37.75M | $125.58M | $30.13M | $33.91M |
| Operating Profit | -$50.89M | -$47.45M | -$152.08M | -$36.52M | -$40.24M |
| Diluted EPS | -$2.32 | -$0.56 | -$1.81 | -$0.56 | -$0.60 |
| Basic EPS | -$2.32 | -$0.56 | -$1.81 | -$0.56 | -$0.60 |
| Non-Operating Interest Income | $4.19M | $2.43M | $3.39M | $1.05M | $1.26M |
| Non-Operating Interest Expense | $210,000.00 | $292,000.00 | $1.52M | $396,000.00 | $399,000.00 |
| Other Income (Expense) | -$5.56M | – | $4.33M | $1.06M | $1.06M |
| Other Non-Operating Income (Expenses) | -$5.56M | – | $4.33M | $1.06M | $1.06M |
| Net Profit | -$52.46M | -$45.32M | -$145.89M | -$34.81M | -$38.33M |
| Profit from Continuing Operations | -$52.46M | -$45.32M | -$145.89M | -$34.81M | -$38.33M |
| Net Income to Parent Company | -$52.46M | -$45.32M | -$145.89M | -$34.81M | -$38.33M |
| Preferred Stock Dividends | $14.49M | $25.56M | $41.04M | $10.18M | $9.78M |
| Net Income to Common Stockholders | -$66.96M | -$70.88M | -$186.93M | -$44.99M | -$48.11M |
| Pretax Profit | -$52.46M | -$45.32M | -$145.89M | -$34.81M | -$38.33M |
Cash flow
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| -Change in Receivables | $0.00 | $0.00 | $360,000.00 | $96,000.00 | $75,000.00 |
| Net Income from Continuing Operations | -$52.46M | -$45.32M | -$145.89M | -$34.81M | -$38.33M |
| Free Cash Flow | -$4.24M | -$49.57M | -$124.02M | -$31.11M | -$34.23M |
| Beginning Cash Balance | $331.89M | $30.57M | $50.14M | $89.96M | $50.14M |
| Net Change in Cash | $758.02M | $301.33M | -$19.57M | -$6.71M | $39.82M |
| Ending Cash Balance | $1.09B | $331.89M | $30.57M | $83.25M | $89.96M |
| Net Other Financing Charges | -$2.54M | $49.37M | – | $0.00 | -$62,000.00 |
| Proceeds from Stock Option Exercised | $584,000.00 | $187,000.00 | $34,000.00 | $9,000.00 | $0.00 |
| Net Preferred Stock Issuance | $0.00 | $305.25M | $67.43M | $0.00 | $67.49M |
| Net Issuance Payments Of Debt | -$3.91M | -$3.90M | -$3.08M | -$144,000.00 | -$140,000.00 |
| Net Cash Flow from Continuing Financing Activities | $795.71M | $350.90M | $64.38M | -$135,000.00 | $67.29M |
| Financing Cash Flow | $795.71M | $350.90M | $64.38M | -$135,000.00 | $67.29M |
| Net Investment Purchase and Sale | -$33.45M | $0.00 | $40.06M | $24.53M | $6.76M |
| Net PPE Purchase and Sale | -$616,000.00 | -$369,000.00 | -$306,000.00 | -$16,000.00 | -$74,000.00 |
| Other Non-Cash Items | $1.75M | $1.74M | $6.63M | $1.62M | $1.61M |
| Depreciation & Depletion & Amortization | $593,000.00 | $606,000.00 | $2.50M | $618,000.00 | $654,000.00 |
| Operating Cash Flow | -$3.62M | -$49.20M | -$123.71M | -$31.09M | -$34.15M |
| Change in Working Capital | $37.52M | -$7.53M | $9.12M | $370,000.00 | $871,000.00 |
| -Change in Prepaid Assets | -$2.55M | -$2.81M | $1.51M | $1.20M | -$1.13M |
| Net cash flow from continuing operations | -$3.62M | -$49.20M | -$123.72M | -$31.09M | -$34.15M |
| -Change in Payables and Accrued Expense | $337,000.00 | -$3.00M | $13.59M | $645,000.00 | $3.44M |
| -Change in Other Current Liabilities | -$1.79M | -$1.72M | -$6.34M | -$1.57M | -$1.51M |
| Net cash flow from investing | -$34.06M | -$369,000.00 | $39.76M | $24.51M | $6.69M |
| Net Cash Flow from Continuing Investing Activities | -$34.06M | -$369,000.00 | $39.76M | $24.51M | $6.69M |
No comments yet — be the first to weigh in on PBLS.
Sign in to join the discussion.